Lifesci Capital Has Negative Estimate for DFTX Q2 Earnings

Definium Therapeutics, Inc. (NASDAQ:DFTX) – Investment analysts at Lifesci Capital dropped their Q2 2026 EPS estimates for Definium Therapeutics in a report released on Friday, May 8th. Lifesci Capital analyst F. Brisebois now expects that the company will earn ($0.55) per share for the quarter, down from their prior estimate of ($0.50). The consensus estimate for Definium Therapeutics’ current full-year earnings is ($1.97) per share. Lifesci Capital also issued estimates for Definium Therapeutics’ Q3 2026 earnings at ($0.51) EPS, Q4 2026 earnings at ($0.55) EPS and FY2026 earnings at ($2.31) EPS.

Definium Therapeutics (NASDAQ:DFTX) last issued its earnings results on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.23).

Other equities analysts have also issued research reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Definium Therapeutics in a research report on Tuesday, April 21st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Definium Therapeutics in a research note on Monday, February 2nd. Leerink Partners upped their price target on shares of Definium Therapeutics from $23.00 to $30.00 and gave the company an “outperform” rating in a research note on Wednesday, April 22nd. Jefferies Financial Group began coverage on shares of Definium Therapeutics in a research note on Thursday, January 29th. They set a “buy” rating and a $30.00 price target on the stock. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $48.00 price target (down from $49.00) on shares of Definium Therapeutics in a research note on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $37.92.

Definium Therapeutics Price Performance

Shares of NASDAQ:DFTX opened at $21.40 on Tuesday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 4.69 and a current ratio of 4.69. The firm has a fifty day moving average price of $20.15 and a 200 day moving average price of $16.17. Definium Therapeutics has a fifty-two week low of $6.16 and a fifty-two week high of $26.25. The firm has a market cap of $2.13 billion, a price-to-earnings ratio of -8.59 and a beta of 2.37.

Institutional Investors Weigh In On Definium Therapeutics

A number of hedge funds have recently bought and sold shares of DFTX. Commodore Capital LP raised its stake in Definium Therapeutics by 10.5% during the second quarter. Commodore Capital LP now owns 5,000,000 shares of the company’s stock valued at $32,450,000 after purchasing an additional 475,000 shares in the last quarter. Orbimed Advisors LLC purchased a new stake in shares of Definium Therapeutics in the third quarter valued at $4,337,000. Rosalind Advisors Inc. raised its stake in shares of Definium Therapeutics by 78.6% in the third quarter. Rosalind Advisors Inc. now owns 750,000 shares of the company’s stock valued at $8,842,000 after acquiring an additional 330,000 shares during the period. Two Sigma Investments LP raised its stake in shares of Definium Therapeutics by 424.9% in the third quarter. Two Sigma Investments LP now owns 296,443 shares of the company’s stock valued at $3,495,000 after acquiring an additional 239,965 shares during the period. Finally, Vanguard Group Inc. raised its stake in shares of Definium Therapeutics by 11.0% in the third quarter. Vanguard Group Inc. now owns 2,012,874 shares of the company’s stock valued at $23,732,000 after acquiring an additional 198,878 shares during the period. Hedge funds and other institutional investors own 27.91% of the company’s stock.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.